Pharmacist-Managed Inpatient Dofetilide Initiation Program: Description and Adherence Rate Post-Root Cause Analysis

Abstract

The aim of this article is to describe the pharmacist-managed dofetilide initiation program at Maine Medical Center (MMC), assess the adherence rate to 8 core clinical metrics, and review adverse effects before and after a root cause analysis (RCA). Core clinical metrics included pharmacist note entered within 4 hours of dose administration, dose chosen correctly per renal function, QTc measurements obtained and reviewed 2 hours after each dose, appropriate dose adjustment per the most recent QTc measurement, documentation of patient education, and assessment of conduction abnormality, drug–drug interactions, and serum potassium and magnesium concentrations. The primary outcome was adherence rate to all 8 core clinical metrics before and after the RCA. The safety outcome was the total number of adverse events. One hundred patients undergoing elective dofetilide initiation were evaluated: 50 pre-RCA and 50 post-RCA. Adherence rate to all core metrics was 14% in the pre-RCA group and 44% in the post-RCA group (P < .001). Torsade de pointes occurred 3 times in the pre-RCA group and never in the post-RCA group. After the RCA, adherence to MMC’s pharmacist-managed inpatient dofetilide initiation program significantly improved.

Keywords

dofetilide pharmacist-managed program quality improvement pharmacy practice

Get full access to this article

View all access options for this article.

References

Pfizer Laboratories Div Pfizer Inc. Tikosyn (dofetilide) [Package Insert]. New York, NY: Pfizer Laboratories Div Pfizer Inc; 2014.

Shenasa

. Dofetilide: electrophysiologic effect, efficacy, and safety in patients with cardiac arrhythmias. Card Electrophysiol Clin. 2016;8(2):423–436.

Pedersen

Bagger

Keller

, et al. Efficacy of dofetilide in the treatment of atrial fibrillation-flutter in patients with reduced left ventricular function: a Danish Investigations of Arrhythmia and Mortality on Dofetilide (Diamond) substudy. Circulation. 2001;104(3):292–296.

Singh

Zoble

Yellen

, et al. Efficacy and safety of oral dofetilide in converting to and maintaining sinus rhythm in patients with chronic atrial fibrillation or atrial flutter: the Symptomatic Atrial Fibrillation Investigative Research on Dofetilide (SAFIRE-D) study. Circulation. 2000;102(19):2385–2390.

Abraham

Saliba

Vekstein

, et al. Safety of oral dofetilide for rhythm control of atrial fibrillation and atrial flutter. Circ Arrhythm Electrophysiol. 2015;8(4):772–776.

Freeland

Worthy

Zolnierz

. Initiation and monitoring of class III antiarrhythmic agents. J Cardiovasc Electrophysiol. 2003;14(suppl 12):S291–S295.

US Food and Drug Administration. Information for Tikosyn (dofetilide). Published January 1, 2016. Accessed June 1, 2017. https://www.fda.gov/Drugs/DrugSafety/ucm489271.htm

Marquis

Degrado

Labonville

, et al. Evaluation of a pharmacist-directed vancomycin dosing and monitoring pilot program at a tertiary academic medical center. Ann Pharmacother. 2015;49(9):1009–1014.

Marshall

Finn

Theodore

. Impact of a clinical pharmacist-enforced intensive care unit sedation protocol on duration of mechanical ventilation and hospital stay. Crit Care Med. 2008;36(2):427–433.

10.

Buckley

Park

Anderson

, et al. Impact of a clinical pharmacist stress ulcer prophylaxis management program on inappropriate use in hospitalized patients. Am J Med. 2015;128(8):905–913.

11.

Meyenburg

Crannage

Murphy

, et al. Evaluation of a pharmacy-managed pharmacokinetic dosing program. J Pharm Pract. 2015;28(6):529–534.

12.

Snider

Kalbfleisch

Carnes

. Initial experience with antiarrhythmic medication monitoring by clinical pharmacists in an outpatient setting: a retrospective review. Clin Ther. 2009;31(6):1209–1218.

13.

Long

VP III

Carnes

Vecchiet

, et al. Evaluation of a pharmacist-managed electrolyte protocol in outpatients on antiarrhythmic medications. J Am Pharm Assoc (2003). 2017;57(4):526–531.

14.

Lifer

Musser

Kier

. Evaluation of a pharmacist-run antiarrhythmic clinic in an ambulatory practice. J Am Pharm Assoc (2003). 2015;55(5):546–551.

15.

Spence

Polzin

Weisberger

, et al. Evaluation of a pharmacist-managed amiodarone monitoring program. J Manag Care Pharm. 2011;17(7):513–522.

16.

Snider

Carnes

Grover

, et al. Cost–benefit and cost-savings analyses of antiarrhythmic medication monitoring. Am J Health Syst Pharm. 2012;69(18):1569–1573.

17.

Rickard

Negrelli

Olson

, et al. Frequency of adverse event monitoring in ambulatory patients on amiodarone or dofetilide. J Pharm Pract. 2018;31(5):457–461.

18.

Dixon

Dunn

Kelly

, et al. Effectiveness of pharmacist-led amiodarone monitoring services on improving adherence to amiodarone monitoring recommendations: a systematic review. Pharmacotherapy. 2016;36(2):230–236.

19.

Quffa

Panna

Kaufmann

, et al. Impact of a pharmacy-cardiology collaborative practice on dofetilide safety monitoring. Ann Pharmacother. 2017;51(1):39–43.

20.

Postema

Wilde

. The measurement of the QT interval. Curr Cardiol Rev. 2014;10(3):287–294.

21.

US Census Bureau. Published July 1, 2017. Accessed August 30, 2017. https://www.census.gov/quickfacts/ME

Supplementary Material

Please find the following supplemental material available below.

For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.

For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.

0.00 MB

0.24 MB